✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Reviewed by Sophie Carter, MPharm — last reviewed 10 May 2026
Quick Answer — Jardiance vs Metformin
Metformin is the universally recommended first-line type-2 diabetes medication: cheap, well-tolerated after the GI settling period, and the only oral diabetes drug shown to reduce all-cause mortality in newly-diagnosed patients (UKPDS 1998). Jardiance (empagliflozin) is a second-line SGLT2 inhibitor that excels at three things metformin can’t touch: cardiovascular death reduction, kidney protection, and heart-failure hospitalization prevention.
For most newly-diagnosed T2DM patients, the answer is “both, in sequence” — start metformin, add Jardiance once HbA1c, kidney function, or cardiovascular risk demands the second tool. They’re complementary, not competitive.
Mechanisms — completely different drugs
The two molecules attack diabetes from opposite ends of the metabolic chain:
- Metformin (biguanide class) — primarily inhibits hepatic gluconeogenesis (your liver dumping glucose into the blood overnight). Secondary actions: improved peripheral insulin sensitivity, reduced intestinal glucose absorption, modest GLP-1 increase. Net effect: lower fasting glucose without forcing the pancreas to make more insulin. Doesn’t cause hypoglycemia as monotherapy.
- Jardiance (SGLT2 inhibitor) — blocks the sodium-glucose co-transporter 2 in the proximal renal tubule, so ~90 g of glucose per day exit in the urine instead of being reabsorbed into the bloodstream. Bypasses insulin and the pancreas entirely. Bonus effects: caloric loss (≈360 kcal/day), modest blood-pressure reduction, sustained osmotic diuresis.
This is why combining the two makes pharmacologic sense — they hit different glucose pools and the actions add up rather than overlap.
HbA1c reduction — head-to-head numbers
Across phase-3 monotherapy trials (matched 24-week endpoints):
| Endpoint | Metformin 2,000 mg/day | Jardiance 25 mg/day |
|---|---|---|
| HbA1c reduction (absolute) | −1.0% to −1.5% | −0.7% to −0.9% |
| Fasting glucose reduction | −40 mg/dL | −25 to −30 mg/dL |
| Weight change at 24 weeks | −1 to −2 kg | −2 to −3 kg |
| Systolic BP change | ≈0 | −4 to −5 mmHg |
| Cardiovascular mortality (T2DM + ASCVD) | Neutral | −38% (EMPA-REG, NEJM 2015) |
| Heart-failure hospitalization (any T2DM) | Neutral | −35% (EMPEROR-Reduced) |
| Renal endpoint (CKD progression) | Neutral | −39% (EMPA-KIDNEY 2023) |
| Hypoglycemia risk (monotherapy) | Very low | Very low |
Metformin lowers HbA1c more. Jardiance does almost everything else better — and that “everything else” is what most kills people with diabetes.
Research Spotlight — EMPA-REG OUTCOME (2015)
This was the trial that changed diabetes care. 7,020 T2DM patients with established cardiovascular disease randomized to empagliflozin or placebo on top of standard care. After 3.1 years: cardiovascular death −38%, all-cause mortality −32%, heart-failure hospitalization −35%. The Kaplan-Meier curves separated within months — far too fast for glucose lowering alone to explain. SGLT2 inhibitors are now considered cardioprotective drugs that happen to lower glucose, not the other way around. Subsequent trials with dapagliflozin (Forxiga) and canagliflozin (Invokana) replicated the cardiac benefit, confirming a class effect.
Side-effect profile — what to actually expect
Metformin first 4–6 weeks: diarrhea, abdominal cramping, metallic taste, nausea — affects ~30% of starters. Almost always resolves with the slow-titration approach: 500 mg with the largest meal for 1 week, then 500 mg twice daily for 1 week, then 1,000 mg twice daily. Extended-release formulations (Glycomet SR, Biciphage 1000 SR) cut GI side effects roughly in half — switch if standard metformin isn’t tolerated. Long-term: vitamin B12 monitoring after year 4 (low B12 in 6–9% of long-term users).
Jardiance: the dominant adverse event is genital mycotic infection (Candida) — affects ~5% of women and ~2% of men. Increased urinary frequency in the first 2–4 weeks. Mild dehydration risk in elderly patients or those on loop diuretics. Rare but important: euglycemic diabetic ketoacidosis (eDKA) — atypical DKA with normal-range glucose, particularly during fasting, illness, or surgery. Hold Jardiance for 3 days before any planned surgery and during acute illness with reduced oral intake.
Cost — the conversation patients actually have
This is where the brand-vs-generic gap becomes meaningful. In the US:
- Metformin generic: $4–10/month at any pharmacy with discount card. WHO-GMP generic from international pharmacy: $3–8/month.
- Brand-name Jardiance: $580–650/month US retail (no insurance), $25–80/month with most insurance plans, $0–25 with manufacturer coupon (commercial insurance only — Medicare excluded).
- WHO-GMP empagliflozin generic from international pharmacy: $35–60/month — about 90% cheaper than US brand.
This is exactly the case where ordering from a licensed international pharmacy turns a cardiovascular-protection medicine many uninsured patients can’t afford into something they can. Patent expiry on Jardiance in the US is 2025–2028 depending on formulation; international generic markets have had it for years.
When metformin is contraindicated
Avoid metformin if: eGFR <30 mL/min, acute heart failure, severe hepatic impairment, contrast imaging within 48 h, alcohol use disorder, or active acidosis. In these patients, Jardiance becomes the de-facto first-line — particularly relevant for the CKD population, where empagliflozin is now indicated down to eGFR 20 mL/min based on the EMPA-KIDNEY trial.
How modern guidelines actually sequence the two
The 2024 ADA/EASD consensus protocol:
- Newly-diagnosed T2DM, no cardiovascular disease, eGFR >45: start metformin. Reassess HbA1c at 3 months.
- Newly-diagnosed T2DM, established ASCVD or heart failure or CKD: start metformin and SGLT2 inhibitor (Jardiance, Forxiga, or Invokana) on day 1. The cardio/renal benefit isn’t worth waiting for.
- HbA1c above goal at 3 months: add SGLT2 inhibitor (or GLP-1 agonist if weight loss is the priority — see Ozempic vs Mounjaro).
- HbA1c still above goal: add a third agent — DPP-4 inhibitor (sitagliptin/Trajenta), pioglitazone (Pioz), or basal insulin.
The era of “metformin alone for years until A1c is 9.5%” is over. Add Jardiance or a GLP-1 agonist sooner rather than later.
Combining the two — what that looks like
Combination therapy is now the default for most T2DM patients within the first 12 months of diagnosis. Two practical approaches:
- Sequential: Metformin 1,000 mg twice daily, then add Jardiance 10 mg once daily after 3 months. Titrate Jardiance to 25 mg if HbA1c remains above goal at month 6.
- Day-one combination: For patients with established cardiovascular or renal disease — metformin 500 mg twice daily for 1 week, then 1,000 mg twice daily, plus Jardiance 10 mg once daily. The fixed-dose combination tablet (empagliflozin/metformin, brand name Synjardy) exists but isn’t widely stocked outside the US/EU.
Where MedsBase fits
We stock the full T2DM ladder so you can build the right regimen:
- Metformin: Glycomet SR (extended-release — gentler GI), Glycomet-GP (metformin + glimepiride combo), Biciphage 1000 SR, Metford, Glycoheal.
- SGLT2 inhibitors: Jardiance (empagliflozin), Forxiga (dapagliflozin), Invokana (canagliflozin).
- Bundle: Diabetes Starter Pack (Glycomet SR 1000 + Glycomet-GP) for newly-diagnosed patients.
- For weight-loss-priority T2DM: see our Ozempic buying guide.
Full ranked menu: Best Diabetes Medications 2026. Category page: Diabetes treatments.
Who is this for
This guide is for adults with type-2 diabetes (or pre-diabetes/insulin resistance) deciding how to start or escalate treatment. If you have type-1 diabetes, neither metformin nor Jardiance is appropriate as monotherapy — both can have a role as adjuncts but require specialist supervision.
Frequently Asked Questions
Can I take Jardiance instead of metformin?
Yes, especially if metformin is contraindicated (CKD with eGFR <30, severe GI intolerance after slow titration). Modern ADA/EASD guidance now allows SGLT2 inhibitors as first-line monotherapy for patients with established cardiovascular or renal disease.
Will Jardiance make me lose weight?
Modestly — 2–3 kg over 6 months on average, primarily through caloric loss in urine (~360 kcal/day). It’s not a weight-loss drug; for that, see GLP-1 agonists (Ozempic, Mounjaro, retatrutide).
Can metformin and Jardiance be taken together?
Yes — they’re routinely combined and the actions add up. Combined HbA1c reduction is roughly the sum of each drug’s monotherapy effect. The fixed-dose combination tablet Synjardy exists but two separate tablets work identically.
Does Jardiance cause weight loss like Ozempic?
Less. Jardiance averages 2–3 kg loss; Ozempic averages 6–8 kg; Mounjaro averages 12–15 kg; retatrutide averages 18–24 kg. SGLT2 inhibitors are mainly for cardio/renal protection — weight loss is a side benefit.
Is the GI upset from metformin permanent?
No. ~85% of patients adapt within 4 weeks if started low and titrated slowly (500 mg with biggest meal for week 1, then add a second 500 mg for week 2, etc.). Switching from immediate-release to extended-release (Glycomet SR, Biciphage SR) cuts GI side effects roughly in half.
Can I drink alcohol on metformin or Jardiance?
Moderate alcohol (≤2 drinks/day) is generally fine on metformin but raises the small lactic-acidosis risk in patients with kidney impairment. On Jardiance, alcohol increases dehydration risk and may precipitate euglycemic DKA in genuinely heavy drinkers. Avoid binge drinking on either.
Do SGLT2 inhibitors really protect kidneys?
Yes — well-established. EMPA-KIDNEY (2023) showed empagliflozin reduced kidney-disease progression by 39% in patients with eGFR 20–90 mL/min, regardless of diabetes status. Jardiance is now first-line for diabetic kidney disease and has expanded indications in non-diabetic CKD.
What’s the urinary tract infection risk on Jardiance?
Genital fungal infections (yeast in women, balanitis in men) — affects ~5% of women, ~2% of men. Bacterial UTI rates are slightly elevated but less dramatically. Risk is highest in the first 8 weeks; good genital hygiene and prompt treatment of any symptoms minimize the issue.
Why is Jardiance so much more expensive than metformin?
Patent protection. Metformin’s patents expired decades ago; Jardiance is still under brand-protection in the US until 2025–2028 depending on formulation. WHO-GMP-certified generic empagliflozin from international markets is ~90% cheaper than US brand price.
If I’m pre-diabetic, should I take metformin or Jardiance?
Metformin is the only one with formal evidence (Diabetes Prevention Program, NEJM 2002) for reducing progression from pre-diabetes to T2DM. Jardiance isn’t indicated for pre-diabetes. For high-risk pre-diabetes, metformin 1,000 mg twice daily plus lifestyle intervention is standard.
🔒 Discreet billing — statement shows your crypto-payment processor (a regulated card-payment processor), never “MedsBase”
🌍 Worldwide Shipping — discreet plain envelope, no pharmacy branding
🛡️ Reshipment Assurance — every order covered
✅ Genuine WHO-GMP-certified manufacturer stock — same molecules as US brand at 1/10 the cost
💳 Credit-card payment guide — how the on-ramp works
📦 Every MedsBase order is covered by our Reshipment Assurance Policy — if your parcel doesn’t arrive within 20 business days, we reship free.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.